Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Multicenter Study of Human Plasma-Derived Factor XIII Concentrate in Congenital Factor XIII Deficiency
2014-003764-20Phase 3
- Sponsor
- CSL Behring
- Start
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Factor XIII (human) in congenital factor XIII deficiency and factor XIII deficiency, sponsored by CSL Behring. Primary endpoint: Adverse Events.
02
Drugs
Factor XIII (human)
03
Conditions
congenital factor XIII deficiencyfactor XIII deficiency
Beyond the preview
Go deeper on 2014-003764-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003764-20.